Latest news
Will Phase III lonvo-z Data and Resumed ATTR Program Change Intellia Therapeutics' (NTLA) Narrative - simplywall.stsimplywall.st · Fri, 07 Aug 2026 13:40:06 GMTIntellia Therapeutics Q2 Earnings Call Highlights - TradingViewTradingView · Fri, 07 Aug 2026 06:04:09 GMTNTLA: Strong Phase 3 data for lonvo-z and robust cash position support operations into 2028 - TradingViewTradingView · Thu, 06 Aug 2026 20:09:49 GMTIntellia Therapeutics reports Q2 2026 net loss of $106.6M, $628.4M cash; positive Phase 3 data for lonvo-z - TradingViewTradingView · Thu, 06 Aug 2026 11:53:01 GMTIntellia Q2 Loss Widens to $106.6 Million as Lonvo-z Advances - Quiver QuantitativeQuiver Quantitative · Thu, 06 Aug 2026 11:51:00 GMTNTLA: Strong Phase 3 data and robust cash position set stage for lonvo-z launch and nex-z progress - TradingViewTradingView · Thu, 06 Aug 2026 11:09:30 GMTIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia TherapeuticsIntellia Therapeutics · Thu, 06 Aug 2026 11:05:12 GMT